SMU-R39 is a TLR7 and TLR8 antagonist with IC50 values of 3.22 µM and 0.24 µM, respectively. SMU-R39 binds to recombinant mTLR7 protein (KD = 2.36 µM) and to recombinant hTLR8 protein (KD = 105 nM). SMU-R39 suppresses downstream NF-kappaB and MAPK signaling, and reduces secretion/transcription of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6) in PBMCs and THP-1 cells. SMU-R39 demonstrates anti-inflammatory efficacy in Imiquimod (IMQ) (HY-B0180)-induced psoriasis mouse model. SMU-R39 can be used for the study of autoimmune diseases such as psoriasis[1].
Molekulargewicht:
387.48
Formel:
C23H25N5O
Target-Kategorie:
NF-kappaB,p38 MAPK,Toll-like Receptor (TLR)
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
